NovoSeven Wins Expanded Indication For Acquired Hemophilia
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.